Improving Human Ovarian Transplantation - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information
First Received Date ^†	January 21, 2009
Last Updated Date	January 21, 2009
Start Date ^†	January 2009
Current Primary Outcome Measures ^† (submitted: January 21, 2009)	improving folliculogenesis and oocuyte maturation after ovarian transplantation [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ^†	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^†
Original Secondary Outcome Measures ^†

Descriptive Information
Brief Title ^†	Improving Human Ovarian Transplantation
Official Title ^†	Phase 1 Study to Improve Results of Human Ovarian Transplantation
Brief Summary	we will perform xenotransplantation and in vitro culture of ovarian tissue from patients undergoing ovarian cortex cryopreservation.
Detailed Description	Ovarian tissue is removed by laparoscopy and only in patients facing premature ovarian failure due to chemotherapy.Tissue for research will consist either of a small portion (<10%) of the cortex for preservation for young women. another source of ovarian tissue for research will be obtained following consent from family of patients who have died of the disease and have previously frozen ovarian tissue.
Study Phase	Phase 0
Study Type ^†	Interventional
Study Design ^†	Treatment, Open Label, Placebo Control, Single Group Assignment, Efficacy Study
Condition ^†	Fertility Preservation
Intervention ^†	Procedure: ovarian transplantation
Study Arms / Comparison Groups	Experimental: tissue will be used for xenotransplantation or in vitro culture
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^†	Active, not recruiting
Estimated Enrollment ^†	100
Estimated Completion Date	January 2015
Estimated Primary Completion Date	January 2012 (final data collection date for primary outcome measure)
Eligibility Criteria ^†	Inclusion Criteria: tissue previously obtained Exclusion Criteria: no tissue available or no consent
Gender	Female
Ages	5 Years to 40 Years
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†
Expanded Access Status

Administrative Information
NCT ID ^†	NCT00827476
Responsible Party	Ariel Revel, Hadassah Medical Organization
Secondary IDs ^††
Study Sponsor ^†	Hadassah Medical Organization
Collaborators ^††	Israel Science Foundation
Investigators ^†
Information Provided By	Hadassah Medical Organization
Verification Date	January 2009
^† Required WHO trial registration data element. ^†† WHO trial registration data element that is required only if it exists.